Day 15 Peripheral Blood Lymphocyte to Monocyte Ratio Post-Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation Predicts Survival in Classical Hodgkin Lymphoma

Abstract Up to 30% of patients with classical Hodgkin lymphoma (cHL) are not responsive to frontline therapy or relapse after primary treatment. In these cases, autologous hematopoietic stem cell transplantation (AHSCT) is the standard of care. The combination of brentuximab vedotin and bendamustine (BV + B) is an effective salvage regimen in this challenging subpopulation. This nationwide multicenter study investigated the real-world efficacy and safety of the BV + B regimen as a bridge to AHSCT in patients with primary refractory or relapsed cHL. A total of 41 cHL patients underwent AHSCT after receiving at least 1 cycle of BV + B (with brentuximab vedotin given at 1.8 mg/kg on day 1 and bendamustine at 90 mg/m2 on days 1–2 every 4 weeks). After a median of 3 (1–6) cycles of BV + B, the objective response rate was 78%, with 29 (70.7%) patients achieving complete remission. Twelve (29.3%) patients relapsed after AHSCT, 2 (4.9%) of them died, while 2 (4.9%) patients are lost to follow-up. After a median of 17 months of follow-up, the estimated 2-year overall- and progression-free survival after AHSCT was 93 and 62%, respectively. Features of advanced disease at recurrence (p = 0.038) and the presence of stage IV cHL at relapse (p = 0.024) are strong predictor markers of unfavorable outcomes. Twenty-four (58.5%) patients experienced adverse events of any grade, while no grade IV toxicities were reported. BV + B is an effective salvage option with a manageable toxicity profile in cHL. The real-world safety and efficacy of this combination are similar to the observations made on the study population.

Download Full-text

Increased circulating CD3+ T cells are associated with early relapse following autologous hematopoietic stem cell transplantation in patients with classical Hodgkin lymphoma

Leukemia & Lymphoma ◽

10.1080/10428194.2019.1581934 ◽

2019 ◽

Vol 60 (10) ◽

pp. 2488-2497 ◽

Cited By ~ 1

Author(s):

Egor V. Batorov ◽

Natalia V. Pronkina ◽

Marina A. Tikhonova ◽

Irina V. Kryuchkova ◽

Vera V. Sergeevicheva ◽

...

Keyword(s):

T Cells ◽

Stem Cell ◽

Hematopoietic Stem Cell Transplantation ◽

Stem Cell Transplantation ◽

Hodgkin Lymphoma ◽

Cell Transplantation ◽

Hematopoietic Stem Cell ◽

Classical Hodgkin Lymphoma ◽

Hematopoietic Stem ◽

Early Relapse

Download Full-text

Infused autograft lymphocyte to monocyte ratio and survival in T-cell lymphomas post-autologous peripheral blood hematopoietic stem cell transplantation.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.e19500 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. e19500-e19500

Author(s):

Luis F. Porrata ◽

David James Inwards ◽

Stephen Maxted Ansell ◽

Ivana N. M. Micallef ◽

Patrick B. Johnston ◽

...

Keyword(s):

Stem Cell ◽

T Cell ◽

Hematopoietic Stem Cell Transplantation ◽

Stem Cell Transplantation ◽

Cell Transplantation ◽

Hematopoietic Stem Cell ◽

Peripheral Blood ◽

Hematopoietic Stem ◽

Lymphocyte To Monocyte Ratio ◽

T Cell Lymphomas

Download Full-text

Endothelial and Circulating Progenitor Cells in Hematological Diseases and Allogeneic Hematopoietic Stem Cell Transplantation

Current Medicinal Chemistry ◽

10.2174/0929867324666171012110244 ◽

2018 ◽

Vol 25 (35) ◽

pp. 4535-4544 ◽

Cited By ~ 4

Author(s):

Annalisa Ruggeri ◽

Annalisa Paviglianiti ◽

Fernanda Volt ◽

Chantal Kenzey ◽

Hanadi Rafii ◽

...

Keyword(s):

Stem Cell ◽

Hematopoietic Stem Cell Transplantation ◽

Stem Cell Transplantation ◽

Cell Transplantation ◽

Hematopoietic Stem Cell ◽

Peripheral Blood ◽

Circulating Endothelial Cells ◽

Hematopoietic Stem ◽

Hematological Diseases

Background: Circulating endothelial cells (CECs), originated form endothelial progenitors (EPCs) are mature cells not associated with vessel walls and detached from the endothelium. Normally, they are present in insignificant amounts in the peripheral blood of healthy individuals. On the other hand, elevated CECs and EPCs levels have been reported in the peripheral blood of patients with different types of cancers and other diseases. Objective: This review aims to provide an overview on the characterization of CECs and EPCs, to describe isolation methods and to identify the potential role of these cells in hematological diseases and hematopoietic stem cell transplantation. Methods: We performed a detailed search of peer-reviewed literature using keywords related to CECs, EPCs, allogeneic hematopoietic stem cell transplantation, and hematological diseases (hemoglobinopathies, hodgkin and non-hodgkin lymphoma, acute leukemia, myeloproliferative syndromes, chronic lymphocytic leukemia). Results: CECs and EPCs are potential biomarkers for several clinical conditions involving endothelial turnover and remodeling, such as in hematological diseases. These cells may be involved in disease progression and in the neoplastic process. Moreover, CECs and EPCs are probably involved in endothelial damage which is a marker of several complications following allogeneic hematopoietic stem cell transplantation. Conclusion: This review provides information about the role of CECs and EPCs in hematological malignancies and shows their implication in predicting disease activity as well as improving HSCT outcomes.

Download Full-text